Tilray Brands (TLRY) Common Equity (2017 - 2026)
Tilray Brands' (TLRY) quarterly Common Equity came in at $1.6 billion in Q2 2026, up 8.38% YoY from $1.5 billion in Q2 2025, and up 3.66% on a QoQ basis from $1.6 billion in Q1 2026.
Tilray Brands (TLRY) Common Equity (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Common Equity data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Common Equity rose 8.38% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through May 2026 was $1.6 billion (up 8.38% YoY) and the FY2026 annual result came in at $1.6 billion, up 8.38% from the prior year.
- Common Equity climbed to $1.6 billion in Q2 2026, from $1.6 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $4.7 billion in Q1 2022 to a low of $1.5 billion in Q2 2025.
- A 5-year average of $3.1 billion and a median of $3.4 billion in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 327.74% — and 2025, when it sank 56.74%.
- Tracing TLRY's Common Equity over 5 years: stood at $4.5 billion in 2022, then fell by 24.31% to $3.4 billion in 2023, then increased by 1.78% to $3.5 billion in 2024, then sank by 55.22% to $1.5 billion in 2025, then increased by 4.39% to $1.6 billion in 2026.
- The last three Common Equity figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Tilray Brands | 512.61 Mn | 277.98 Mn | 90.52 Mn | 1.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1.61 Bn |
| Feb 28, 2026 | 1.56 Bn |
| Nov 30, 2025 | 1.55 Bn |
| Aug 31, 2025 | 1.52 Bn |
| May 31, 2025 | 1.49 Bn |
| Feb 28, 2025 | 2.70 Bn |
| Nov 30, 2024 | 3.45 Bn |
| Aug 31, 2024 | 3.48 Bn |
| May 31, 2024 | 3.44 Bn |
| Feb 29, 2024 | 3.34 Bn |
| Nov 30, 2023 | 3.39 Bn |
| Aug 31, 2023 | 3.40 Bn |
| May 31, 2023 | 3.33 Bn |
| Feb 28, 2023 | 3.41 Bn |
| Nov 30, 2022 | 4.48 Bn |
| Aug 31, 2022 | 4.56 Bn |
| May 31, 2022 | 4.44 Bn |
| Feb 28, 2022 | 4.66 Bn |
| Nov 30, 2021 | 4.47 Bn |
| Aug 31, 2021 | 4.39 Bn |